Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Purpose of review Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is not commonly used due to myelosuppressive effects of valganciclovir. In this article, the role of the newly approved antiviral compound, letermovir, is reviewed. Recent findings Letermovir inhibits CMV by interfering viral terminase complex. In a phase 3 randomized placebo-controlled clinical study that enrolled 495 CMV-seropositive HSCT recipients, the primary end point of clinically significant CMV infection was significantly reduced by letermovir prophylaxis. Letermovir was well tolerated without risk of myelotoxicity and nephrotoxicity. Experimental in-vitro data suggest that letermovir may possess low genetic barrier to resistance. In prophylaxis trials, two breakthrough infections were reported due to selection of CMV UL56 V236M mutation. Summary Letermovir is an important addition to the current strategies for CMV prevention after allogeneic HSCT. Its favourable efficacy and safety profile re-opens door for antiviral prophylaxis another first-line option, similar to CMV surveillance-preemptive therapy, for preventing CMV in allogeneic HSCT recipients.

Original languageEnglish (US)
Pages (from-to)286-291
Number of pages6
JournalCurrent Opinion in Infectious Diseases
Volume31
Issue number4
DOIs
StatePublished - Aug 1 2018

Fingerprint

Hematopoietic Stem Cell Transplantation
Cytomegalovirus Infections
Cytomegalovirus
Antiviral Agents
AIC246
Opportunistic Infections
Placebos
Safety
Mutation
Therapeutics
Infection

Keywords

  • cytomegalovirus
  • ganciclovir
  • letermovir
  • mutations
  • resistance
  • transplantation

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{aee80ac599a34301b1454b7d82c640b2,
title = "Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation",
abstract = "Purpose of review Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is not commonly used due to myelosuppressive effects of valganciclovir. In this article, the role of the newly approved antiviral compound, letermovir, is reviewed. Recent findings Letermovir inhibits CMV by interfering viral terminase complex. In a phase 3 randomized placebo-controlled clinical study that enrolled 495 CMV-seropositive HSCT recipients, the primary end point of clinically significant CMV infection was significantly reduced by letermovir prophylaxis. Letermovir was well tolerated without risk of myelotoxicity and nephrotoxicity. Experimental in-vitro data suggest that letermovir may possess low genetic barrier to resistance. In prophylaxis trials, two breakthrough infections were reported due to selection of CMV UL56 V236M mutation. Summary Letermovir is an important addition to the current strategies for CMV prevention after allogeneic HSCT. Its favourable efficacy and safety profile re-opens door for antiviral prophylaxis another first-line option, similar to CMV surveillance-preemptive therapy, for preventing CMV in allogeneic HSCT recipients.",
keywords = "cytomegalovirus, ganciclovir, letermovir, mutations, resistance, transplantation",
author = "Razonable, {Raymund R}",
year = "2018",
month = "8",
day = "1",
doi = "10.1097/QCO.0000000000000459",
language = "English (US)",
volume = "31",
pages = "286--291",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation

AU - Razonable, Raymund R

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose of review Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is not commonly used due to myelosuppressive effects of valganciclovir. In this article, the role of the newly approved antiviral compound, letermovir, is reviewed. Recent findings Letermovir inhibits CMV by interfering viral terminase complex. In a phase 3 randomized placebo-controlled clinical study that enrolled 495 CMV-seropositive HSCT recipients, the primary end point of clinically significant CMV infection was significantly reduced by letermovir prophylaxis. Letermovir was well tolerated without risk of myelotoxicity and nephrotoxicity. Experimental in-vitro data suggest that letermovir may possess low genetic barrier to resistance. In prophylaxis trials, two breakthrough infections were reported due to selection of CMV UL56 V236M mutation. Summary Letermovir is an important addition to the current strategies for CMV prevention after allogeneic HSCT. Its favourable efficacy and safety profile re-opens door for antiviral prophylaxis another first-line option, similar to CMV surveillance-preemptive therapy, for preventing CMV in allogeneic HSCT recipients.

AB - Purpose of review Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is not commonly used due to myelosuppressive effects of valganciclovir. In this article, the role of the newly approved antiviral compound, letermovir, is reviewed. Recent findings Letermovir inhibits CMV by interfering viral terminase complex. In a phase 3 randomized placebo-controlled clinical study that enrolled 495 CMV-seropositive HSCT recipients, the primary end point of clinically significant CMV infection was significantly reduced by letermovir prophylaxis. Letermovir was well tolerated without risk of myelotoxicity and nephrotoxicity. Experimental in-vitro data suggest that letermovir may possess low genetic barrier to resistance. In prophylaxis trials, two breakthrough infections were reported due to selection of CMV UL56 V236M mutation. Summary Letermovir is an important addition to the current strategies for CMV prevention after allogeneic HSCT. Its favourable efficacy and safety profile re-opens door for antiviral prophylaxis another first-line option, similar to CMV surveillance-preemptive therapy, for preventing CMV in allogeneic HSCT recipients.

KW - cytomegalovirus

KW - ganciclovir

KW - letermovir

KW - mutations

KW - resistance

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=85049859223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049859223&partnerID=8YFLogxK

U2 - 10.1097/QCO.0000000000000459

DO - 10.1097/QCO.0000000000000459

M3 - Review article

C2 - 29746444

AN - SCOPUS:85049859223

VL - 31

SP - 286

EP - 291

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 4

ER -